The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Cited by
Sorted by citations
Items 401–500 of 1,000
Tsur, A., Cahn, A., Israel, M., Feldhamer, I., Hammerman, A., & Pollack, R. M. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3355 · Cited by 21
Bahmad, H. F., Poppiti, R., & Alexis, J. B. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.02.025 · Cited by 21
Gadager, B. B., Tang, L. H., Ravn, M. B., Doherty, P., Harrison, A. S., Christensen, J., Taylor, R. S., Zwisler, A., & Maribo, T. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02723-5 · Cited by 22
Otto, T., Diesing, J., Borchert, J., Heitmann, E., Schloot, N. C., Lebrec, J., Müller‐Wieland, D., & Häckl, D. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14924 · Cited by 20
Lv, Y., Li, K., Wang, S., Wang, X., Yue, G., Zhang, Y., Lv, X., Zhao, P., Wang, S., Zhang, Q., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02123-3 · Cited by 20
RetractedLife expectancy with and without cognitive impairment by diabetes status among older Americans
Díaz-Venegas, C., Schneider, D. C., Myrskylä, M., & Mehta, N. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0190488 · Cited by 20
Gæde, J., Oellgaard, J., Ibsen, R., Gæde, P., Nørtoft, E., Parving, H., Kjellberg, J., & Pedersen, O. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4739-3 · Cited by 20
Kim, G. S., Park, J. H., & Won, J. C. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.2.106 · Cited by 20
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.025 · Cited by 20
Burggraaf, B., Pouw, N. M. C., Fernández‐Arroyo, S., der Zee, L. C. V. V., van de Geijn, G. M., Birnie, E., Huisbrink, J., van der Zwan, E. M., Mulder, M. T., Rensen, P. C. N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13960 · Cited by 21
Aleppo, G., DeSalvo, D. J., Lauand, F., Huyett, L. M., Chang, A., Vienneau, T., & Ly, T. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01366-9 · Cited by 19
Duration of diabetes-related complications and mortality in type 1 diabetes: a national cohort study
Bjerg, L., Guðbjörnsdóttir, S., Franzén, S., Carstensen, B., Witte, D. R., Jørgensen, M. E., & Svensson, A. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyaa290 · Cited by 19
Self-citationDas, A. K., Saboo, B., & Unnikrishnan, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s294842 · Cited by 21
Cai, C., Liu, Y., Li, Y., Shi, Y., Zou, H., Bao, Y., Shen, Y., Cui, X., Fu, C., Jia, W., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0897-7 · Cited by 19
Saeed, M., Stene, L. C., Ariansen, I., Tell, G. S., Tapia, G., Joner, G., & Skrivarhaug, T. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01498-5 · Cited by 20
Taimour, S., Franzén, S., Zarrouk, M., Acosta, S., Nilsson, P. M., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.01.063 · Cited by 19
Self-citationEffect of type 2 diabetes medications on fracture risk
Guja, C., Guja, L., & Miulescu, R. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.51 · Cited by 20
Morieri, M. L., Longato, E., Mazzucato, M., Camillo, B. D., Cocchiglia, A., Gubian, L., Sparacino, G., Avogaro, A., Fadini, G. P., & de Kreutzenberg, S. V. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0922-1 · Cited by 19
Low-dose phloretin alleviates diabetic atherosclerosis through endothelial KLF2 restoration
Xia, Y., Feng, H., Li, Z., Tang, K., Gao, H., Wang, W., Cui, X., & Li, X.-L. (2019) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2019.1699396 · Cited by 19
Bjerg, L., Dalsgaard, E., Norman, K., Isaksen, A. A., & Sandbæk, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060410 · Cited by 19
Gurung, R. L., Yiamunaa, M., Liu, S., Liu, J., Chan, C., Choo, R. W. M., Ang, K., Sum, C. F., Subramaniam, T., & Lim, S. C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0867-4 · Cited by 19
Mertens, J., Weyler, J., Dirinck, E. L., Vonghia, L., Kwanten, W. J., Gaal, L. F. V., Winter, B. Y. D., Francque, S., & Block, C. E. M. D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02764-y · Cited by 20
Zeng, Z., Yu, C., Chen, R., Li, Z., Wang, P., Wang, X., Li, X., & Zheng, Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02855-w · Cited by 18
Guandalini, G. S., & Bangalore, S. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.020 · Cited by 18
Riveline, J., Vergès, B. L., Detournay, B., Picard, S., Benhamou, P., Bismuth, É., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101306 · Cited by 19
Carrera, M. J., Moliner, P., Llauradó, G., Enjuanes, C., Conangla, L., Chillarón, J. J., Ballesta, S., Climent, E., Colet, J. C., & Roux, J. A. F. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010006 · Cited by 19
Liu, Y., Ning, X., Zhang, L., Long, J., Liang, R., Peng, S., Wang, H., Li, Y., Chen, W., & Xiao, H. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002720 · Cited by 19
Khan, F., Gonçalves, I., Shore, A. C., Natali, A., Palombo, C., Colhoun, H. M., Östling, G., Casanova, F., Kennbäck, C., Aizawa, K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100676 · Cited by 18
Buchmann, M., Tuncer, O., Auzanneau, M., Eckert, A. J., Rosenbauer, J., Reitzle, L., Heidemann, C., Holl, R. W., & Thamm, R. (2023) · PubMed Central · doi:10.25646/11439 · Cited by 18
Ibrahim, A. E., Maged, K., Elhenawee, M., & El‐Hay, S. S. A. (2023) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2023.101199 · Cited by 18
Mariaca, K., Serés‐Noriega, T., Viñals, C., Perea, V., Conget, I., Mesa, A., Boswell, L., Font, C., Pané, A., Vinagre, I., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.017 · Cited by 18
Safdar, N. Z., Kietsiriroje, N., & Ajjan, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015328 · Cited by 20
Viñals, C., Conget, I., Granados, M., Giménez, M., & Amor, A. J. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01616-4 · Cited by 19
Garofolo, M., Russo, E., Miccoli, R., Lucchesi, D., Giusti, L., Sancho‐Bornez, V., Daniele, G., Prato, S. D., & Penno, G. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.03.012 · Cited by 18
Dijk, W., & Cariou, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13636 · Cited by 19
Lan, N. S. R., Fegan, P. G., Rankin, J. M., Bell, D. A., Watts, G. F., & Yeap, B. B. (2019) · Diabetic Medicine · doi:10.1111/dme.14095 · Cited by 18
Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b
Zare, M., Panahi, G., Koushki, M., Mostafavi‐Pour, Z., & Meshkani, R. (2019) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2019.1680700 · Cited by 18
O’Reilly, J. E., Blackbourn, L. A. K., Caparrotta, T. M., Jeyam, A., Kennon, B., Leese, G., Lindsay, R. S., McCrimmon, R. J., McGurnaghan, S. J., McKeigue, P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05173-w · Cited by 18
Self-citationFumaria parviflora improves liver damage and lipid profile changes in STZ-induced diabetic rats
Kooshki, F., Niazkar, H. R., Shirazi, S., Azar, V. A., & Karimi, A. (2020) · Physiology and Pharmacology · doi:10.32598/ppj.24.3.80 · Cited by 18
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 19
Bradić, J., Milosavljevic, I. M., Bolevich, S. S., Litvitskiy, P. F., Jeremic, N. S., Bolevich, S., Zivkovic, V. I., Srejovic, I. M., Jeremic, J. N., Jovicic, N. U., et al. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13450 · Cited by 18
Jin, Q., Lau, E. S. H., Luk, A. O. Y., Ozaki, R., Chow, E., Cheng, F., So, T., Yeung, T., Loo, K.-M., Lim, C. K. P., et al. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108015 · Cited by 18
Birkeland, E., Gharagozlian, S., Birkeland, K. I., Holm, O. K. S., Thorsby, P. M., & Aas, A. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.70 · Cited by 18
Fadini, G. P., Prato, S. D., Avogaro, A., & Solini, A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14599 · Cited by 19
Insulin Pump Therapy and Continuous Glucose Monitoring
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Laimer, M., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199568604.001.0001 · Cited by 18
Chen, W.-H., Li, Y., Yang, L., Allen, J. M., Shao, H., Donahoo, W. T., Billelo, L., Hu, X., Shenkman, E. A., Bian, J., et al. (2024) · PLOS ONE · doi:10.1371/journal.pone.0297208 · Cited by 17
Obesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Cardiovascular Magnetic Resonance as Pathophysiologic Tool in Diabetes Mellitus
Mavrogeni, S. I., Bacopoulou, F., Markousis‐Mavrogenis, G., Giannakopoulou, A., Kariki, O. K., Vartela, V., Kolovou, G. D., Charmandari, E., & Chrousos, G. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672302 · Cited by 17
Christoforidis, A., Georeli, I., Dimitriadou, M., Galli‐Τsinopoulou, A., & Stabouli, S. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3555 · Cited by 17
Adult-onset type 1 diabetes: A changing perspective
Burahmah, J., Zheng, D., & Leslie, R. D. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.06.003 · Cited by 18
Smidtslund, P., Sigfrids, F. J., Ylinen, A., Elonen, N., Harjutsalo, V., Groop, P., & Thorn, L. M. (2022) · Diabetes Care · doi:10.2337/dc22-1586 · Cited by 18
Jung, H., Sung, Y., Hong, Y. S., Song, D. K., Hong, S., & Lee, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280929 · Cited by 17
Voeltz, D., Brinks, R., Tönnies, T., & Hoyer, A. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003156 · Cited by 17
Dhabhai, B., Dhakar, R., Ranga, V., Surolia, P. K., Menon, A. M., Sharma, N. K., Dakal, T. C., & Lohar, D. (2023) · Medinformatics · doi:10.47852/bonviewmedin32021408 · Cited by 18
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Song, D. K., Hong, Y. S., Sung, Y., & Lee, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299035 · Cited by 19
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
Hibi, M., Hari, S., Yamaguchi, T. F., Mitsui, Y., Kondo, S., & Katashima, M. (2019) · Nutrients · doi:10.3390/nu11092126 · Cited by 17
Risk factor reduction in type 2 diabetes demands a multifactorial approach
Rydén, L., Ferrannini, G., & Mellbin, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319872015 · Cited by 17
Berg, A. K., Thorsen, S. U., Thyssen, J. P., Zachariae, C. O. C., Keiding, H., & Svensson, J. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0368 · Cited by 17
Kanumilli, N., Brunton, S., Cos, X., Deed, G., Kushner, P. R., Lin, P., & Nolte, J. E. S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107813 · Cited by 17
Falkentoft, A. C., Zareini, B., Andersen, J., Wichmand, C. H., Hansen, T. B., Selmer, C., Schou, M., Gæde, P., Stæhr, P., Hlatky, M. A., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab065 · Cited by 17
Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes
Vestberg, D., Rosengren, A., Eeg‐Olofsson, K., Miftaraj, M., Franzén, S., Svensson, A., & Lind, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000727 · Cited by 17
Self-citationMartínez‐Hervás, S., Sánchez‐García, V., Herrero-Cervera, A., Vinué, Á., Real, J. T., Ascaso, J. F., Burks, D. J., & Navarro, H. G. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1977-1 · Cited by 17
Sefidgari‐Abrasi, S., Karimi, P., Roshangar, L., Morshedi, M., Bavafa-Valenlia, K., Saghafi‐Asl, M., Mohiti, S., & Rahimiyan‐Heravan, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4745389 · Cited by 17
Pop‐Busui, R., Repetto, E., Baron, J. M., Schumacher, D., Vaduganathan, M., & Pandey, A. (2025) · Diabetes Care · doi:10.2337/dc25-1260 · Cited by 16
Microalbuminuria and retinopathy in adolescents and young adults with type 1 and type 2 diabetes
Ek, A. E., Samuelsson, U., Janson, A., Carlsson, A., Elimam, A., & Marcus, C. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13074 · Cited by 16
Bryk, A. H., Konieczyńska, M., Polak, M., Plicner, D., Bochenek, M., & Undas, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01230-9 · Cited by 16
Keys, M. T., Thinggaard, M., Larsen, L. A., Pedersen, D. A., Hallas, J., & Christensen, K. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac200 · Cited by 16
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
Yang, J., Yang, H., Cao, L., Yin, Y., Shen, Y., & Zhu, W. (2022) · Medicine · doi:10.1097/md.0000000000031799 · Cited by 17
Qin, Y.-N., & Zheng, X. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01165-z · Cited by 16
Avdic, T., Carlsen, H. K., Rawshani, A., Guðbjörnsdóttir, S., Mandalenakis, Z., & Eliasson, B. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02226-x · Cited by 18
Self-citationKocher, T., Meisel, P., Baumeister, S. E., & Holtfreter, B. (2024) · Periodontology 2000 · doi:10.1111/prd.12592 · Cited by 16
Amor, A. J., Ortega, E., Giménez, M., Cofán, M., Blanco, J., Pané, A., Boswell, L., Vinagre, I., Esmatjes, E., & Conget, I. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.02.004 · Cited by 17
Kalashnikov, V. Y., Vikulova, O. K., Zheleznyakova, A. V., Исаков, М. А., Bondarenko, I. Z., Shestakova, M. V., & Dedov, I. I. (2019) · Diabetes Mellitus · doi:10.14341/dm10167 · Cited by 16
Taimour, S., Avdic, T., Franzén, S., Zarrouk, M., Acosta, S., Nilsson, P. M., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2019) · Vascular Medicine · doi:10.1177/1358863x19870243 · Cited by 16
Self-citationSingh, P., Gonçalves, I., Tengryd, C., Nitulescu, M., Persson, A. F., To, F., Bengtsson, E., Volkov, P., Orho‐Melander, M., Nilsson, J. Å., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01189-z · Cited by 16
Herzog, K., Andersson, T., Grill, V., Hammar, N., Malmström, H., Talbäck, M., Walldius, G., & Carlsson, S. (2021) · Diabetes Care · doi:10.2337/dc21-1238 · Cited by 16
Case Fatality of Patients With Type 1 Diabetes After Myocardial Infarction
Kerola, A. M., Juonala, M., Palomäki, A., Semb, A. G., Rautava, P. T., & Kytö, V. (2022) · Diabetes Care · doi:10.2337/dc22-0042 · Cited by 16
Weng, S., Lin, C.-F., Hsu, C., & Lin, S. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00972-0 · Cited by 17
Smoking and coronary artery disease risk in patients with diabetes: A Mendelian randomization study
Chen, S., Yang, F., Xu, T., Wang, Y., Zhang, K., Fu, G., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.891947 · Cited by 17
Vernstrøm, L., Funck, K. L., Grove, E. L., Laugesen, E., Baier, J. M., Hvas, A., & Poulsen, P. L. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.11.013 · Cited by 16
Luo, Y. L., Lü, K., Liu, G., Wang, J., Laurent, I., & Zhou, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0707-4 · Cited by 16
Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Jermendy, G., Kempler, P., Barkai, L., & Wittmann, I. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3190 · Cited by 16
Edqvist, J., Rawshani, A., Adiels, M., Bjorck, L. M., Lind, M., Svensson, A., Gudbjörnsdottir, S., Sattar, N. A., & Rosengren, A. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013871 · Cited by 16
Self-citationHero, C., Karlsson, S. A., Franzén, S., Svensson, A., Miftaraj, M., Guðbjörnsdóttir, S., Sundell, K. A., Eliasson, B., & Eeg‐Olofsson, K. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01115-w · Cited by 16
Self-citationCardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Michels, A. W., Brusko, T. M., Evans‐Molina, C., Homann, D., Richardson, S. J., & Powers, A. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf267 · Cited by 16
At the heart of the matter: Cardiovascular health challenges among incarcerated women
Grammatikopoulou, M. G., Lampropoulou, M., Milapidou, M., & Goulis, D. G. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.05.002 · Cited by 15
DPARD: rationale, design and initial results from the Dutch national diabetes registry
Bak, J. C. G., Mul, D., Serné, E. H., de Valk, H. W., Sas, T., Geelhoed-Duijvestijn, P. H. L. M., Kramer, M. H. H., Nieuwdorp, M., & Verheugt, C. L. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00782-x · Cited by 15
Wang, M., Francis, F., Kunz, H., Zhang, X., Wan, C., Liu, Y., Taylor, P., Wild, S. H., & Wu, H. (2022) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2022.100072 · Cited by 15
Teixeira, P. F., Battelino, T., Carlsson, A., Guðbjörnsdóttir, S., Hannelius, U., von Herrath, M., Knip, M., Korsgren, O., Larsson, H. E., Lindqvist, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06089-5 · Cited by 16
Serés‐Noriega, T., Perea, V., & Amor, A. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041097 · Cited by 15
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 15
Frampton, R., SNAITH, J. R., HOCKING, S. L., Holmes-Walker, D. J., Olsen, N., & Greenfield, J. R. (2024) · Diabetic Medicine · doi:10.1111/dme.15377 · Cited by 15
Parental Psychosocial Variables and Glycemic Control in T1D Pediatric Age: A Systematic Review
Costa, V., Pereira, B., Patton, S. R., & Brandão, T. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01566-y · Cited by 15
New approach to diabetes care: From blood glucose to cardiovascular disease
Aguíar, C., Duarte, R., & Carvalho, D. M. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.01.001 · Cited by 15
Tandon, T., Dubey, A. K., Srivastava, S., Manocha, S., Arora, E., & Hasan, N. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_22_19 · Cited by 15
Valsesia, A., Kulkarni, S. S., Marquis, J., Leone, P., Mironova, P., Walter, O., Hjorth, M. F., Descombes, P., Hager, J., Saris, W. H. M., et al. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy363 · Cited by 15
Thunander, M., Lindgren, A., Petersson, C., Landin‐Olsson, M., & Holmberg, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107943 · Cited by 15
Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus
Santiago, J. C. H., Delgado, J. M., Blanco, M. C., Saez, J. B. L., & Gómez-Fernández, P. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.05.014 · Cited by 15
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
